Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-03

Study Completion Date

2019-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transversal multicentric French study on the microbiota in patients with Crohn's disease and their first degree healthy relatives The primary objective is the comparison of microbiota between patients with CD, healthy controls non genetically linked and first degree healthy relatives of patients with CD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Search for New Genetic Mutations Major Effect in Crohn's Disease

NCT02851134

Crohn Disease

COMPLETED

Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases

NCT02878395

Crohn Disease

UNKNOWN

COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)

NCT02839317

Crohn's Disease

COMPLETED

Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin

NCT06972901

Crohn Disease (CD) Ileocolic Resection Post-endoscopic Operative Reccurence

RECRUITING NA

Impact of the Fecal Flora Transplantation on Crohn's Disease

NCT02097797

Crohn's Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Crohn's disease is a chronic inflammatory bowel disease associating flares and remission periods. Its etiology is unknown and there are no specific therapy. CD affects young patients and has a major impact on quality of life. There are few population-based studies and there are about 2.5 million affected patients in Europe and North America. From data from EPIMAD Registry the number of affected patients in France should be 200 000. The Crohn's disease pathogenesis is bad known; It coul be the results of the activation of the gastro-intestinal immune system toward gut microbiota in genetically susceptible hosts. In CD patients there is an important ecologic modification of the flora with an excess of Bacteroidetes and Proteobacteria and a decrease of anti inflammatory bacteria (Firmicutes). In ileum of CD patients a specific E Coli (adherent and invasive E Colo) is found in two thirds of cases.The presence of this AIEC seems to be associated to the variant NOD2 (results from our team in multiplex families).

In a family with at least 1 patient with CD, the healthy first degree relatives present a high risk (\* 10) to also develop a CD.

The primary objective is the comparison of microbiota between patients with CD, healthy controls non genetically linked and first degree healthy relatives of patients with CD. The first endpoint is the Lachnospiraceae rates in each group.

The secondary objectives are :

1. the search for an association between bacterial dysbiosis and different genetic backgrounds in patients with CD, their first degree healthy relatives and controls.
2. the quantification of potential invasive bacteria with invasive properties (E. coli including adherent-invasive E. coli, Shigella, Salmonella, Yersinia, Campylobacter), and fecal fungal flora (Candida albicans, in particular) and their association with genetic and serological profiles in patients with CD, their healthy relatives and control subjects.
3. a study of environmental risk factors using a questionnaire to be submitted to CD patients, their healthy relatives and control subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease Genetic Predisposition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

case Crohn disease

60 cases with Crohn's Disease

biomarkers

Intervention Type OTHER

fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms

first relative healthy

2 healthy relatives per CD case (total 120)

biomarkers

Intervention Type OTHER

fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms

controls

60 controls matched on gender and age with CD cases

biomarkers

Intervention Type OTHER

fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biomarkers

fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dysbiosis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient with Crohn's disease

* Patient \> 18 years old
* Having at least one first degree health relative
* OK to participate to the project

First degree healthy relatives

* specific clinical questionnaire and dosing fecal calprotectin to ensure the absence of inflammatory pathology.
* OK to participate to the project

Exclusion Criteria

* Intestinal resection.
* Pregnant or breastfeeding woman.
* subject under guardianship
* subject does not speak French
* person unable to speak
* taking antibiotics or bowel preparation will push 6 weeks stool specimens, after cessation treatments.

Minimum Eligible Age

8 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes